Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein α activity in lung cancer

Journal of the National Cancer Institute

Volumn 98, Issue 6, 2006, Pages 396-406

  Tada, Yasuhiro ^a   Brena, Romulo Martin ^a   Hackanson, Björn ^a,c   Morrison, Carl ^b   Otterson, Gregory A ^a   Plass, Christoph ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CCAAT ENHANCER BINDING PROTEIN ALPHA; GENOMIC DNA; HISTONE H3; HISTONE H4; METHYL CPG BINDING PROTEIN 2; RNA; TRICHOSTATIN A; UPSTREAM STIMULATORY FACTOR; 5 AZA 2' DEOXYCYTIDINE 5' PHOSPHATE; 5-AZA-2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE; AZACITIDINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; MBD2 PROTEIN, HUMAN; MECP2 PROTEIN, HUMAN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GEL MOBILITY SHIFT ASSAY; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA ISOLATION; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; SOUTHERN BLOTTING; CHEMISTRY; CPG ISLAND; DNA SEQUENCE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MUTAGENESIS; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE;

ACETYLATION; AZACITIDINE; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CARCINOMA, NON-SMALL-CELL LUNG; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; METHYL-CPG-BINDING PROTEIN 2; MUTAGENESIS; PROMOTER REGIONS (GENETICS); SEQUENCE ANALYSIS, DNA; UPSTREAM STIMULATORY FACTORS;

EID: 33644958558     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj093     Document Type: Article

References (38)

1. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
2. Wistuba II, Gazdar AF. Characteristic genetic alterations in lung cancer. Methods Mol Med 2003;74:3-28.
3. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer. 9: Molecular biology of lung cancer: Clinical implications. Thorax 2003;58:892-900.
4. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
5. Hsu HS, Wen CK, Tang YA, Lin RK, Li WY, Hsu WH, et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res 2005;11:5410-6.
6. Irimia M, Wen CK, Tang YA, Esteller M. Promoter hypermethylation of the predominant mechanism in the context of a wild-type K-ras in lung cancer. Oncogene 2004;23:8695-9.
7. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-17.
8. Li J, Zhang Z, Dai Z, Popkie AP, Plass C, Morrison C, et al. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer. Neoplasia 2003;5:362-6.
9. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002;21:6915-35.
10. Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A, Tannehill-Gregg S, et al. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene 2004;23:3521-9.
11. Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer 2004;41:170-7.
12. Birkenmeier EH, Gwynn B, Howard S, Jerry J, Gordon JI, Landschulz WH, et al. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 1989;3:1146-56.
13. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 1997;94:569-74.
14. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
15. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
16. Flodby P, Barlow C, Kylefjord H, Ahrlund-Richter L, Xanthopoulos KG. Increased hepatic cell proliferation and lung abnormalities in mice defi cient in CCAAT/enhancer binding protein alpha. J Biol Chem 1996;271:24753-60.
17. McKnight SL. McBindall - a better name for CCAAT/enhancer binding proteins? Cell 2001;107:259-61.
18. Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, et al. Impaired energy homeostasis in C/EBP alpha knockout mice. Science 1995;269:1108-12.
19. Watkins PJ, Condreay JP, Huber BE, Jacobs SJ, Adams DJ. Impaired proliferation and tumorigenicity induced by CCAAT/enhancer-binding protein. Cancer Res 1996;56:1063-7.
20. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG. Down-regulation and antiproliferative role of C/EBPα in lung cancer. Cancer Res 2002;62:528-34.
21. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002;99:1332-40.
22. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002;62:4048-53.
23. Smiraglia DJ, Fruhwald MC, Costello JF, McCormick SP, Dai Z, Peltomaki P, et al. A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics 1999;58:254-62.
24. Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, Raval A, et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet 2003;12:791-801.
25. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002;99:3740-5.
26. Timchenko N, Wilson DR, Taylor LR, Abdelsayed S, Wilde M, Sawadogo M, et al. Autoregulation of the human C/EBP α gene by stimulation of upstream stimulatory factor binding. Mol Cell Biol 1995;15:1192-202.
27. Bird AP, Wolffe AP. Methylation-induced repression - belts, braces, and chromatin. Cell 1999;99:451-4.
28. Cross SH, Meehan RR, Nan X, Bird A. A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nat Genet 1997;16:256-9.
29. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22:6335-45.
30. Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, Bird AP. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 2005;19:667-78.
31. Nerlov C. C/EBPα mutations in acute myeloid leukaemias. Nat Rev Cancer 2004;4:394-400.
32. Halmos B, Basseres DS, Monti S, D'Alo F, Dayaram T, Ferenczi K, et al. A transcriptional profi ling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 β as a novel tumor suppressor in lung cancer. Cancer Res 2004;64:4137-47.
33. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000;249:135-64.
34. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004;24:1270-8.
35. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2004:163-83.
36. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al. Addition of rituximab to fl+udarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
37. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;63:7089-93.
38. Momparler RL, Ayoub J. Potential of 5-aza-2′ -deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001;34 Suppl 4:S111-5.